Nanodelivery system enhances the immunogenicity of dengue-2 nonstructural protein 1, DENV-2 NS1

Jearanaiwitayakul, Tuksin; Sunintaboon, Panya; Chawengkittikul, Runglawan; Limthongkul, Jitra; Midoeng, Panuwat; Warit, Saradee; Ubol, Sukathida

doi:10.1016/j.vaccine.2020.08.021

Cited by 17 publications

(31 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The RBD-loaded nanoparticles were prepared by ionotropic gelation as previously described [ 23 ]. Briefly, a sodium tripolyphosphate (TPP, 0.167 mg/mL) solution mixed with RBD protein (0.3 mg/mL) was added dropwise into a TMC solution in a HEPES buffer (pH 7.4) containing 1% ( v/v ) Tween 80 under continuous stirring for 1 h at room temperature.…”

Section: Methodsmentioning

confidence: 99%

“…The supernatant was harvested for estimating the amount of unbound RBD by Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA). The efficiency of protein loading in TMC NPs was calculated as described previously [ 23 ]. To characterize the physical properties of NPs, the mean of particle size, polydispersity index (PDI) and the zeta potential were evaluated by a zetasizer (Malvern Instruments Ltd., Malvern, UK).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2

et al. 2021

Self Cite

View full text Add to dashboard Cite

Mucosal immunity plays a significant role in host defense against viruses in the respiratory tract. Because the upper respiratory airway is a primary site of SARS-CoV-2 entry, immunization at the mucosa via the intranasal route could potentially lead to induction of local sterilizing immunity that protects against SARS-CoV-2 infection. In this study, we evaluated the immunogenicity of a receptor-binding domain (RBD) of SARS-CoV-2 spike glycoprotein loaded into N,N,N-trimethyl chitosan nanoparticles (RBD-TMC NPs). We showed that intranasal delivery of RBD-TMC NPs into mice induced robust local mucosal immunity, as evidenced by the presence of IgG and IgA responses in BALs and the lungs of immunized mice. Furthermore, mice intranasally administered with this platform of immunogens developed robust systemic antibody responses including serum IgG, IgG1, IgG2a, IgA and neutralizing antibodies. In addition, these immunized mice had significantly higher levels of activated splenic CD4+ and CD8+ cells compared with those that were administered with soluble RBD immunogen. Collectively, these findings shed light on an alternative route of vaccination that mimics the natural route of SARS-CoV-2 infection. This route of administration stimulated not only local mucosal responses but also the systemic compartment of the immune system.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, Jearanaiwitayakul et al prepared nanovaccine composed of non-structural protein (NS1) of dengue virus (PENV) vaccine and TMC by the ionic gelation method to protect dengue virus as the most common mosquito-borne viral disease [ 45 ]. The nanovaccine potentially stimulated monocyte-derived DCs (MoDCs) and resulted in increased expression of CD83 as the maturation marker, and CD80 and CD86 as costimulating molecules, and marked secretion of innate immune cytokines.…”

Section: Mucoadhesive Polymeric Particulate Systemmentioning

confidence: 99%

Mucosal Vaccine Delivery Using Mucoadhesive Polymer Particulate Systems

Cho

Hwang

et al. 2021

Tissue Eng Regen Med

View full text Add to dashboard Cite

Vaccination has been recently attracted as one of the most successful medical treatments of the prevalence of many infectious diseases. Mucosal vaccination has been interested in many researchers because mucosal immune responses play part in the first line of defense against pathogens. However, mucosal vaccination should find out an efficient antigen delivery system because the antigen should be protected from degradation and clearance, it should be targeted to mucosal sites, and it should stimulate mucosal and systemic immunity. Accordingly, mucoadhesive polymeric particles among the polymeric particles have gained much attention because they can protect the antigen from degradation, prolong the residence time of the antigen at the target site, and control the release of the loaded vaccine, and results in induction of mucosal and systemic immune responses. In this review, we discuss advances in the development of several kinds of mucoadhesive polymeric particles for mucosal vaccine delivery.

show abstract

“…VLPs based DENV vaccines are described by Zhang et al, 2020, but none of them were developed with NS1 proteins [53]. One example is given with C-terminal truncated DENV-2 NS1 loaded in N,N,N, trimethyl chitosan nanoparticles (NS11-279TMC NPs) investigated in murine model and in human ex vivo [40]. In human ex vivo model, it has been demonstrated that TMC particles deliver NS11-279 protein in monocyte-derived dendritic cells (MODCs) and also stimulate those cells resulting in an increase expression of maturation marker (CD83), costimulatory molecules (CD80, CD86 and HLA-DR) and secreting diverse immune cytokines/chemokines [40].…”

Section: Figure 4 Denv Ns1-based Vaccine Platformsmentioning

confidence: 99%

“…Immunization with NS11-279TMC NPs resulted in both B cell and T cell responses leading to IgG production and CD8+ T cells activation. One important finding is that DENV2 NS11-279directed antibodies have ability to kill DENV-infected cells through antibody dependent complement-mediated cytotoxicity [40]. Consequently, a such NS1-based vaccine candidate is of great interest in relation to the properties of TMC as a suitable adjuvant which enhances delivery and promote immunogenicity of viral antigen.…”

Section: Figure 4 Denv Ns1-based Vaccine Platformsmentioning

confidence: 99%

Viral Toxin ns1 as Pivotal Target in Development of Efficient Dengue Vaccine

Lebeau¹,

Lagrave²,

Ogire³

et al. 2021

Preprint

View full text Add to dashboard Cite

Mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often associated to fatality. To date, there are no specific medications to treat dengue and prevent the risk of hemorrhage. Dengue is caused by one of the four related antigenically distinct serotypes, DENV-1 to DENV-4. The growing burden that represents the four DENV serotypes has intensified both basic and applied researches to better understand the dengue physiopathology. It has been proposed a significant role for the secreted soluble DENV nonstructural protein 1 (sNS1) glycoprotein in the pathogenesis of severe dengue. Here, we provided an overview on current knowledge about the role of sNS1 in the immunopathogenesis of dengue disease. The reasons for the consideration of sNS1 in the design of future dengue vaccine candidates will be discussed.

show abstract

Nanodelivery system enhances the immunogenicity of dengue-2 nonstructural protein 1, DENV-2 NS1

Cited by 17 publications

References 51 publications

Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2

Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2

Mucosal Vaccine Delivery Using Mucoadhesive Polymer Particulate Systems

Viral Toxin ns1 as Pivotal Target in Development of Efficient Dengue Vaccine

Contact Info

Product

Resources

About